Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses

doi:10.5306/wjco.v12.i2.103

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7223)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

343

WORD

193

HTML

2936

Figures (1-3)

269

Tables (1-4)

604

Sum=4345

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

308

Download

763

Sum=1071

Publishing Process of This Article

Item

Count

Browse

611

Download

1196

Sum=1807

Feb 24, 2021 (publication date) through Jan 6, 2025

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Feb 24, 2021; 12(2): 103-114
Published online Feb 24, 2021. doi: 10.5306/wjco.v12.i2.103

Table 2 Patient characteristics

				irAE
	Overall			Yes			No			P value
	n	mean	SD	n	mean	SD	n	mean	SD
Age at ICPi initiation	293	63.3	12.8	91	66.1	13.2	202	62.0	12.4	0.0108

irAE: Immune-related adverse events; ICPi: Immune checkpoint inhibitors.

Citation: Peravali M, Gomes-Lima C, Tefera E, Baker M, Sherchan M, Farid S, Burman K, Constantinescu F, Veytsman I. Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses. World J Clin Oncol 2021; 12(2): 103-114
URL: https://www.wjgnet.com/2218-4333/full/v12/i2/103.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i2.103